ArticleThe journal of allergy and clinical immunology. Global2026
Epidemiology of penicillin allergy labels in a general Swedish population.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Penicillin allergy prevalence is reported in up to 10% of patients and is linked to broad-spectrum antibiotic overuse, extended hospitalizations, and higher mortality. Its prevalence has not previously been evaluated in Sweden. Objective: The aim of this study was to investigate the prevalence and characteristics of penicillin allergy labels (PALs) in the electronic medical records of 3 Swedish regions (1,088,000 inhabitants). Methods: A retrospective analysis of PALs in the electronic medical records in the Southeast Healthcare Region of Sweden and estimation of point prevalence were performed. Two nonoverlapping cohorts were defined by label complexity: a simple cohort with pre-2017, nonstandardized labels identified by keywords (n = 7,514), and a complex cohort (n = 22,736) with post-2017, standardized labels identified using Anatomical Therapeutic Chemical codes. Results: Point prevalence of PALs was 2.8% across all regions (69.6% female). Differences were noted across the 3 regions for the different phenotypes. The regional prevalences of skin symptoms were 15.9-32.2% for urticaria and angioedema, 2.4-23.8% for maculopapular or undefined rash, and 4.9-7.6% for flushing. Severe reactions were rare (3.0-6.9%). Mild nonallergic symptoms appeared in 1.9-2.0%, with unclear symptoms in 24.4-64.7%. The most prevalent culprits were narrow-spectrum penicillins (32.9-48.1%). Multidrug-resistant bacteria were significantly more prevalent in all regions among patients with a PAL (Östergötland, Conclusion: Overall, 2.8% of the study population carried a PAL. Labels need to be better documented: Up to two thirds lacked sufficient information to determine the phenotype and other characteristics of the reactions. Moreover, antimicrobial resistance was more prevalent among patients with a PAL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.